BIFILAC Capsule contains Streptococcus faecalis T-110, Clostridium butyricum TO-A, Bacillus mesentericus TO-A which are patented strains, licensed from TOA Pharmaceuticals Co. Ltd, Japan and Lactic acid bacillus (Lactobacillus sporogenes), which is a time-tested probiotic strain. Through their symbiotic action they produce certain factors which inhibit bad micro-organisms and in addition, also produce a bifidogenic nutrient which helps in increasing the count of beneficial micro-organisms in the intestine.
• Streptococcus faecalis T-110 JPC - 30 million
• Clostridium butyricum TO-A - 2 million
• Bacillus mesentericus TO-A - 1 million
• Lactic acid bacillus (Lactobacillus sporogenes) - 50 million